BeyondSpring Inc. (NASDAQ: BYSI) has announced its financial results for the year ended December 31, 2025, highlighting significant clinical advancements and operational progress. The company reported a net loss of $8.7 million, a slight improvement from the $8.9 million loss in 2024. Cash and cash equivalents stood at $12.6 million as of December 31, 2025, reflecting a solid financial position to support ongoing clinical trials. Notably, BeyondSpring's lead program, Plinabulin, demonstrated a statistically significant overall survival benefit in a Phase 3 study for non-small cell lung cancer (NSCLC) patients, leading to plans for a confirmatory trial, DUBLIN-4. This trial aims to further validate the efficacy of Plinabulin in patients who have progressed on immune checkpoint inhibitors. The company also reported advancements in its SEED Therapeutics division, which initiated its first clinical trial for a novel oral RBM39 degrader, ST-01156, following IND clearance in both the U.S. and China. The completion of a $30 million Series A-3 financing further strengthens BeyondSpring's financial position, allowing for continued investment in its clinical programs. Overall, the results reflect a year of strategic growth and clinical validation, positioning BeyondSpring for a promising 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.